About Exelixis
Exelixis is a company based in San Francisco (United States) founded in 1994.. The company has 1,150 employees as of December 31, 2024. Exelixis has completed 3 acquisitions, including Agritope, X-Ceptor Therapeutics and Xceptor. Exelixis offers products and services including CABOMETYX and COMETRIQ. Exelixis operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter San Francisco, United States
- Employees 1150 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Exelixis, Inc.
-
Annual Revenue
$2.17 B18.49as on Dec 31, 2024
-
Net Profit
$521.27 M150.89as on Dec 31, 2024
-
EBITDA
$718.75 M265.59as on Dec 31, 2024
-
Latest Funding Round
$366.84 K (USD), Grant
Jan 01, 2021
-
Investors
HHS
& 2 more
-
Employee Count
1150
as on Dec 31, 2024
-
Investments & Acquisitions
Agritope
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Exelixis
Exelixis is a publicly listed company on the NASDAQ with ticker symbol EXEL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Exelixis
Exelixis offers a comprehensive portfolio of products and services, including CABOMETYX and COMETRIQ. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for advanced neuroendocrine tumors and other cancers.
Cabozantinib-based therapy for specific cancer types.
Unlock access to complete
Leadership Team
113 people
Finance and Accounting
23 people
Sales and Marketing
23 people
Software Development Team
23 people
Senior Team
21 people
Legal and Compliance
21 people
Product Management Team
11 people
Human Resources and Administration
10 people
Unlock access to complete
Funding Insights of Exelixis
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $366,835
-
First Round
First Round
(08 Aug 2005)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Grant - Exelixis | Valuation |
investors |
|
| Jun, 2020 | Amount | Grant - Exelixis | Valuation |
investors |
|
| Aug, 2016 | Amount | Post-IPO - Exelixis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Exelixis
Exelixis has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, European Union and OSTI.GOV. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Scientific and technical information is managed and disseminated by OSTI.GOV.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Exelixis
Exelixis has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Agritope, X-Ceptor Therapeutics and Xceptor. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Data automation software is provided for financial markets operations.
|
2003 | ||||
|
Nuclear receptor modulating small molecule drugs for metabolism and cardiovascular diseases
|
1999 | ||||
|
Developer of transgenic varieties of fruit and vegetable crops
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Exelixis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Exelixis Comparisons
Competitors of Exelixis
Exelixis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Exelixis
Frequently Asked Questions about Exelixis
When was Exelixis founded?
Exelixis was founded in 1994 and raised its 1st funding round 11 years after it was founded.
Where is Exelixis located?
Exelixis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
How many employees does Exelixis have?
As of Dec 31, 2024, the latest employee count at Exelixis is 1,150.
What is the annual revenue of Exelixis?
Annual revenue of Exelixis is $2.17B as on Dec 31, 2024.
What does Exelixis do?
Exelixis was founded in 1994 in San Francisco, United States, within the biotechnology sector. Small molecule therapeutics for oncology are developed, with a focus on inhibiting key enzymes and proteins. Cabozantinib, the lead product, targets receptor tyrosine kinases for metastatic medullary thyroid cancer treatment. Cobimetinib addresses melanoma, while XL888 functions as an oral HSP90 inhibitor affecting regulatory proteins. Operations center on advancing cancer therapies through clinical and preclinical research.
Who are the top competitors of Exelixis?
Exelixis's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Exelixis offer?
Exelixis offers CABOMETYX and COMETRIQ.
Is Exelixis publicly traded?
Yes, Exelixis is publicly traded on NASDAQ under the ticker symbol EXEL.
How many acquisitions has Exelixis made?
Exelixis has made 3 acquisitions, including Agritope, X-Ceptor Therapeutics, and Xceptor.
Who are Exelixis's investors?
Exelixis has 3 investors. Key investors include HHS, European Union, and OSTI.GOV.
What is Exelixis's ticker symbol?
The ticker symbol of Exelixis is EXEL on NASDAQ.